Among numerous anti-PD1-/PD-L1 monoclonal antibodies (mAbs) in the global market, six currently FDA/EMA-approved mAbs to either target PD-1 (i.e., nivolumab, pembrolizumab, cemiplimab) or PD-L1 (i.e., durvalumab, atezolizumab, avelumab) are under intense investigation across multiple cancer types [177]. Here, CD274 is linked to cancer.